All News
Filter News
Found 56,803 articles
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
-
The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
-
Empirical Bioscience’s 2019 RT-qPCR Kit Available For Use in nCoV Assay Testing
4/6/2020
Empirical Bioscience announced that their QuanTASE and QuanTASE PLUS One Step RT-qPCR RT-qPCR Kits have been successfully tested in assays using EUA authorized qPCR detection kits using the established CDC testing protocol.
-
GAC Beneficiary Houston Methodist Investigates Immunotherapy Techniques to Curb COVID-19
4/6/2020
Golfers Against Cancer takes pride in identifying research projects dedicated to specific work targeting various forms of cancer.
-
Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
4/6/2020
Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs.
-
Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform
4/6/2020
Theranica Bioelectronics (Theranica), a bio-medical technology company developing advanced electroceuticals for migraine and other pain conditions, today announced availability of Nerivio™ on UpScript's direct-to-patient telemedicine platform.
-
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo NodularisConference call today at 8.30am EDT
4/6/2020
Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis (PN), studies MTI-105 and MTI-106
-
IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program
4/6/2020
IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter (“CRL”) that it recently received from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm
-
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
4/6/2020
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic.
-
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19
4/6/2020
Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system.
-
iBIO Commends Illinois the Life Sciences Community for its Impact through the iBIO COVID-19 PPE Response Fund
4/6/2020
iBIO today announced that since the March 23rd launch of the iBIO COVID-19 PPE Response Fund, the Illinois life sciences community is making a significant impact in the fight against the coronavirus.
-
Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19
4/6/2020
Successfully obtained clones for all three selected Coronavirus Antigens
-
CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)CareDx works with International Consortium of Transplant Leaders on a Global Registry of Transplant Patients Diagnosed with COVID-19
4/6/2020
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the COVID-19 Transplant Registry (C19TxR.org).
-
Thermo Fisher Scientific Provides COVID-19 Business Update and Will Hold First Quarter Earnings Conference Call on Wednesday, April 22, 2020
4/6/2020
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, due to the evolving COVID-19 pandemic and related customer impact, it is withdrawing 2020 annual guidance, which was provided on January 30, 2020 . Thermo Fisher has mobilized to support the global COVID-19 response with produc
-
BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics
4/6/2020
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.
-
Centene Announces New Benefits For Employees During COVID-19 Pandemic
4/6/2020
Centene (NYSE: CNC) today announced that it is establishing a Medical Reserve Leave policy to support clinical staff who want to join a medical reserve force and serve their communities, during the COVID-19 pandemic.
-
Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19
4/6/2020
Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-β antisense drug candidate, announced today that Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500
-
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic
4/6/2020
Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the company’s response, operationally and scientifically. Dear Generex Shareholders, The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain tim
-
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
4/6/2020
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European patent office has granted the divisional patent application titled "Formulations and Metho